EFM1 Antibody

EMA-1: A Primordial Germ Cell Surface Marker Antibody

EMA-1 is a monoclonal antibody (IgM isotype) developed against mouse primordial germ cells. It recognizes monofucosylated and difucosylated polylactosamine glycolipids on glycoproteins .

EFm1: A Bacteriophage Endolysin with Antimicrobial Activity

EFm1 is a biomaterial endolysin derived from the E. faecalis phage IME-EF1, not an antibody. It exhibits potent lytic activity against E. faecalis, a clinically significant pathogen .

Key Features

• Domains:

  • N-terminal CHAP domain (1–145 aa): Catalyzes peptidoglycan hydrolysis.

  • C-terminal domain (166–237 aa): Forms a tetrameric structure critical for bacterial cell wall binding .

• Lytic Spectrum:

  • Targets 22/23 tested E. faecalis clinical strains (e.g., ATCC29212, V583) .

  • Inactive against E. coli and Bacillus subtilis .

Comparative Analysis of EMA-1 and EFm1

Research Gaps and Clarifications

No peer-reviewed studies or commercial products referencing an "EFM1 Antibody" were identified. Potential reasons include:

1. Nomenclature Variants: "EFM1" may refer to a protein or gene not yet linked to antibody development.

2. Typographical Errors: Possible confusion with EMA-1 or EFm1.

3. Emerging Research: The compound might be in early-stage development without published data.

Recommendations for Further Investigation

• Validate the intended target (e.g., confirm if "EFM1" refers to EFm1 or EMA-1).

• Explore structural databases (e.g., PDB, UniProt) for unindexed antibodies.

• Screen patent filings for proprietary antibodies under development.